Conference Call and Webcast Today at 8:30 a.m. ET Actively dosing patients in OCU400 Phase 3 liMeliGhT clinical trialOCU410 preliminary safety and efficacy data expected later this year Expanded...
MALVERN, Pa., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel...
MALVERN, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and...
MALVERN, Pa., July 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0.0002 | 0.001 | 1.0E-6 | 6466 | 0.00022187 | CS |
4 | -0.0004 | -66.6666666667 | 0.0006 | 0.002 | 1.0E-6 | 13179 | 0.00099634 | CS |
12 | -0.0028 | -93.3333333333 | 0.003 | 0.0095 | 1.0E-6 | 91333 | 0.00302856 | CS |
26 | -0.0008 | -80 | 0.001 | 0.07 | 1.0E-6 | 225397 | 0.01440969 | CS |
52 | -0.0008 | -80 | 0.001 | 0.07 | 1.0E-6 | 225397 | 0.01440969 | CS |
156 | -0.0008 | -80 | 0.001 | 0.07 | 1.0E-6 | 225397 | 0.01440969 | CS |
260 | -0.0008 | -80 | 0.001 | 0.07 | 1.0E-6 | 225397 | 0.01440969 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.